S-1/A: First Choice Healthcare Pivots to Primary Care, Launches IPO

First Choice Healthcare Solutions, Inc. (FCHS) is undertaking a strategic pivot from its legacy orthopedic business to a national chain of primary care and wellness clinics, supported by a new public offering of Series D Convertible Preferred Stock and Warrants.

Summary

• FCHS is transitioning its business model from orthopedic services to developing a national network of primary care and wellness clinics, focusing on life improvement and pharmacy services.
• The company plans to terminate all remaining legacy orthopedic and physical therapy services.
• A new corporate structure will be implemented, with the company rebranding as Leading Primary Care, Inc., and operating through subsidiaries: Live Well Medical Group, The Good Clinic Properties, Inc., and Live Well Drugstore, Inc.
• FCHS is acquiring Pointe Medical Services, Inc., Pointe Med Pharmacy, Inc., Livewell MD, LLC, and Livewell Drugstore, LLC (collectively 'Pointe Med Pharmacy') for $15.8 million, payable in cash, debt assumption/payoff, stock, earn-out, and performance bonus.
• The company is also acquiring the physical and intangible assets of The Good Clinic, Inc. for $3.5 million in an all-stock deal.
• The new strategy aims to leverage Nurse Practitioners for primary care, projecting a 25% margin improvement over traditional MD-staffed clinics.
• Services will include preventive care, acute/chronic disease management, women's/men's/pediatric/geriatric health, mental health, and health education, expected to generate 85% of clinic-level revenue.
• An additional 15% of projected clinic revenue will come from self-pay quality-of-life services such as anti-aging, hormone replacement therapy, Botox, cosmetic dermatology, medically assisted weight management, and biohacking.
• A centralized compounding pharmacy (LiveWell Drugstore) will provide personalized medications, with plans to expand to 503B status for broader supply capabilities.
• The company intends to raise $12.0 million in gross proceeds from the public offering of 2,400,000 shares of Series D Convertible Preferred Stock and accompanying Warrants at $5.00 per unit, with net proceeds of $10.64 million (or $12.296 million if over-allotment is exercised).
• A 1-for-2,000 reverse stock split will be effected for existing common shares prior to NYSE listing, but will not apply to shares issued in the IPO, resale offering, or for acquisitions/debt exchange.
• 720,000 shares of common stock are being offered for resale by existing selling stockholders at a fixed price of $5.00 per share until NYSE listing.
• The CEO's Series A Super Voting Preferred Stock will be cancelled upon completion of the offering, and the board will be expanded with new independent directors.
• FCHS reported net losses of $3.5 million and $3.8 million for the nine months ended September 30, 2025, and the year ended December 31, 2024, respectively, and has an accumulated deficit of $71.3 million as of September 30, 2025.
• Pointe Med/LiveWell, the acquired entity, reported net income attributable to shareholders of $1.44 million for the nine months ended September 30, 2025, and $1.41 million for the year ended December 31, 2024, showing profitability.

Sentiment

Score: 4

Explanation: The company is undergoing a significant strategic pivot and capital raise following a history of substantial losses and bankruptcy. While the new strategy in primary care and wellness, coupled with recent acquisitions, presents a potential growth path and the acquired entity shows profitability, the overall financial position of FCHS remains weak with a 'going concern' warning. The offering is critical for survival and execution, but the risks associated with integration, competition, and regulatory compliance are high, making it a highly speculative investment.

Positives

• The strategic pivot to primary care and wellness clinics, focusing on high-growth markets and life improvement services, offers a clear new direction for the company.
• The acquisition of Pointe Med/LiveWell and The Good Clinic provides established assets and a foundation for the new business model, including an operating compounding pharmacy.
• Pointe Med/LiveWell has demonstrated profitability, with net income attributable to shareholders increasing significantly from $164,672 in FY2023 to $1,414,493 in FY2024, and further to $1,444,050 for the nine months ended September 30, 2025.
• The use of Nurse Practitioners is expected to provide an approximate 25% margin improvement over traditional physician-staffed primary care offices due to lower labor costs.
• The planned centralized administrative infrastructure is designed to achieve economies of scale and sustain profit margins as the network of clinics expands.
• The cancellation of the CEO's Series A Super Voting Preferred Stock and the appointment of new independent directors will improve corporate governance and reduce concentrated voting power.
• The company aims to list its common stock on the NYSE, which could enhance liquidity and investor visibility.
• The PPP loan forgiveness of $471,300 in 2025 and $812,324 in 2024 has reduced debt burden.

Negatives

• First Choice Healthcare Solutions, Inc. (FCHS) has a history of significant net losses, including $3.5 million for the nine months ended September 30, 2025, and an accumulated deficit of $71.3 million.
• The company has experienced recurring cash outflows from operations, indicating ongoing liquidity challenges.
• The "going concern" warning highlights substantial doubt about the company's ability to continue operations without securing additional capital.
• The company's past was marred by criminal charges against its former CEO, bankruptcy proceedings, and damage to its reputation and relationships.
• The strategic pivot is a new, unproven business plan, and there is no assurance it will achieve profitability or effectively manage growth.
• The reliance on self-pay services for 15% of projected clinic revenue introduces revenue volatility and bad debt risks, potentially impacting financial projections.
• The anti-dilution provisions of the Series D Convertible Preferred Stock, with no floor price on conversion, could lead to substantial future dilution for common shareholders.
• The company's ability to pay dividends in cash is limited by Delaware law, requiring available surplus or net profits, which FCHS currently lacks.
• The market for healthcare services is highly competitive, with established virtual and brick-and-mortar competitors, posing a challenge to market penetration and profitability.

Risks

• The company has posted minimal profit since commencing operations and has a limited operating history in its new primary care clinic model, making future performance evaluation difficult.
• Cash from operations may be insufficient to meet current or future operating needs, expenditures, and debt service obligations, potentially leading to substantial liquidity problems.
• Failure to raise additional capital will necessitate curtailing or ceasing operations.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies or assets.
• Opening new clinic sites in multiple markets may strain resources, increase demands on management, and lead to difficulties in managing growth, potentially harming business and financial results.
• Changes in tax laws and unanticipated tax liabilities could adversely affect the effective income tax rate and ability to achieve profitability.
• Quarterly financial results are expected to fluctuate significantly due to demand for services, client retention, economic conditions, marketing costs, and expansion expenses.
• Volatility in financial markets could make future financing difficult or more expensive, adversely affecting business and financial condition.
• Potential profit margins may decline due to increasing pricing pressure in the industry.
• High indebtedness ($24.7 million as of Dec 31, 2024) could dedicate substantial cash flow to debt service, reduce financial flexibility, and make it difficult to obtain additional financing.
• Pandemics, epidemics, natural disasters, terrorist activities, and political unrest could materially impact business, operations, financial condition, and cash flows.
• Acquisitions involve risks such as difficulties in integration, failure to achieve anticipated benefits, and challenges in maintaining effective internal controls.
• Inability to attract and retain qualified medical professionals (Nurse Practitioners) could negatively affect operations, patient attraction, and new clinic openings.
• Medical professional liability risks could be costly to defend and negatively impact financial results.
• The evolving healthcare regulatory and political framework, including changes in laws and regulations, could adversely affect financial condition and results of operations.
• The highly regulated healthcare industry and pharmacy practice expose the company to compliance risks, potential fines, and exclusion from federal programs for non-compliance.
• Compounding pharmacies are dependent on the consistent availability and quality of base pharmaceuticals, and supply chain disruptions could significantly decrease revenue and service scope.
• Federal and state laws protecting privacy and security of protected health information (HIPAA, HITECH) may increase costs and limit data use, subjecting the company to penalties for non-compliance.
• Reliance on the self-pay model for quality-of-life services introduces revenue volatility, bad debt risks, pricing challenges, and increased administrative costs.
• Changes in third-party reimbursement rates or methods for medical services could reduce demand or create downward pricing pressure, harming financial position.
• Federal and state restrictions on advertising may adversely affect the ability to advertise clinics and services.
• Failure to maintain effective internal controls in accordance with Sarbanes-Oxley Act could harm business and stock price.
• The market for healthcare services is highly competitive, with larger, better-financed competitors, potentially leading to reduced demand or downward pricing pressure.
• A decline in consumer disposable income could adversely affect clinical visits and financial results.
• The company is a smaller reporting company, and reduced disclosure requirements may make its common stock less attractive to investors.
• Being a public company may strain resources and distract management.
• Management has broad discretion in the use of net proceeds from the offering and may not use them effectively.
• A limited trading market for common stock exists, and an active market may not develop, impairing liquidity and ability to raise capital.
• The market for common stock may fluctuate significantly due to various factors, including regulatory changes, reimbursement policies, and loss of key personnel.
• The issuance of common stock from convertible preferred stock and warrants could cause substantial dilution.
• Resales by selling stockholders may adversely affect the market price of common stock.
• The company has not paid dividends in the past and has no immediate plans to do so.
• Quarterly operating results are expected to fluctuate, potentially causing stock price decline.
• Penny stock rules may make buying or selling securities difficult, reducing liquidity.
• The former CEO's criminal charges and bankruptcy tarnished the company's reputation.
• Charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.

Future Outlook

The company's future outlook is centered on a strategic pivot to become a national chain of innovative primary care and wellness clinics, focusing on life improvement services and pharmacy operations. It expects to commence operations for this new strategy by October 1, 2025, with a plan to open five clinics by December 2025 and a total of thirty new clinics within the next four years. The strategy relies on leveraging Nurse Practitioners for improved margins and a centralized administrative infrastructure for cost efficiencies. The company anticipates significant growth in the medical weight loss, hormone replacement therapy, peptides, regenerative medicine, and biohacking markets. However, the ability to achieve these goals is contingent on successfully raising additional capital, integrating acquisitions, managing growth, and navigating a highly competitive and regulated healthcare environment.

Management Comments

• We are actively engaged in pivoting the Company's strategy away from our historic orthopedic business model to a strategy of developing a national chain of innovative primary care and wellness clinics focused on providing life improvement services and pharmacy services.
• We will terminate all of our remaining legacy orthopedic and Physical Therapy services and focus the company resources on our strategy of building and operating primary care and wellness clinics.
• Our go forward strategy will be executed using a corporate structure of centralized management services designated as Leading Primary Care, Inc. with three operating subsidiaries.
• We are confident in the market size of our business opportunity, the strength of our strategy, and the experience of our management team.
• We believe our strategy of combining a full suite of primary care services and the specialized services of our competition in an operational environment focused on providing high quality care, excellent customer experience, personalized care plans and personalized medications has the potential to deliver our desired financial performance.
• It is our plan that the cost of our back-office operations will not increase in direct relation to the growth of our network of primary care clinics, which will allow us to sustain profit margins across our business operations with a cost effective and scalable back office.
• We believe that the scalable structure of our administrative back-office functions can efficiently support our expansion plans.

Industry Context

The company's strategic pivot aligns with broader healthcare trends emphasizing primary care, personalized medicine, and wellness services, driven by an aging population, rising chronic conditions, and unsustainable healthcare expenditures. The market for primary care is valued at $271.0 billion in 2023, with an expected CAGR of 3.36% from 2024 to 2030. The pharmaceutical weight loss market is projected to grow from $6 billion to $100 billion by 2030, and the hormone replacement therapy market from $6.9 billion to $13.4 billion by 2032. The peptides market is also expected to see significant growth, and regenerative medicine and biohacking are rapidly expanding. The company aims to differentiate itself by combining comprehensive primary care with specialized quality-of-life services and an internal compounding pharmacy, leveraging Nurse Practitioners for cost efficiency. This strategy positions the company to capitalize on the demand for integrated, patient-centric healthcare, but it faces intense competition from established virtual and brick-and-mortar providers.

Comparison to Industry Standards

• The company's strategy to utilize Nurse Practitioners (NPs) for primary care is noted to provide an approximate 25% margin improvement over traditional primary care offices staffed with medical doctors, based on Bureau of Labor Statistics data (May 2023 median annual pay for NP: $126,260 vs. Family Medicine Physicians: $240,790) and CMS reimbursement rates (NPs reimbursed at 85% of physician rates).
• The company's EMR system fully complies with Stages 1 and 2 Meaningful Use standards defined by the Centers for Medicare & Medicaid Services Incentive Programs, indicating adherence to federal electronic health record requirements.
• The company's compounding pharmacy aims to achieve PCAB accreditation for Sterile, Non-Sterile, and Hazardous Drug compounding and handling, which certifies it as meeting or exceeding pharmaceutical compounding industry standards and all State and Federal pharmacy regulations.
• The company's business model is compared to virtual competitors like Hims, Ro, REX MD, Renew Youth (men's health), Alloy, Midi (women's health), and brick-and-mortar clinics such as Revibe, Herself Health, Oak Street Medical, or One Medical, as well as individual private practices. The company aims to differentiate by offering a full suite of primary care and specialized services in an operational environment focused on high-quality care, excellent customer experience, personalized care plans, and personalized medications.

Management Changes

Corporate Governance

Legal Proceedings

• Former CEO Christian C. Romandetti, Sr. was arrested on November 15, 2018, and pled guilty to conspiracy to commit securities fraud, which led to the company's bankruptcy.
• The company and its subsidiaries filed for Chapter 11 bankruptcy on June 15, 2020, and emerged on April 27, 2022, with all litigation settled or converted into unsecured creditors as part of the reorganization plan.
• A settlement agreement with Steward Healthcare eliminated a $7.5 million put option held by Steward.
• An outstanding accounts payable liability of approximately $1,200,000 remains from a lease settlement with GMR Melbourne, LLC, following a breach of contract complaint filed on September 20, 2021.
• A judgment of $19,473 was granted against the company on January 25, 2024, for an equipment lease, subsequently settled for $9,000 in March 2024.
• CBL & Associates Properties, Inc. is seeking $84,051 for defaulted lease payments, which the company has accrued and is working to settle.
• A motion for summary judgment was granted against the company on December 12, 2023, for $102,884 (including fees) in a breach of lease agreement complaint filed by MBABJB Holdings Family Limited Partnership.
• Ackerman, LLP, bankruptcy counsel, was awarded $548,000 in fees, with $203,115 remaining unpaid after partial satisfaction of the judgment.
• The company has been involved in employment-related matters, primarily due to unpaid wages following staff reductions, with most cases settled.

Related Party Transactions

• Lease agreement for clinic space with Live Well Realty, LLC, a related party.
• Notes payable to CEO Lance Friedman totaling $2,142,105 as of September 30, 2025, and $1,626,983 as of December 31, 2024, related to deferred compensation, payments to third-party service providers, and normal business items.
• Notes payable to the prior Chief Financial Officer totaling $151,858 as of September 30, 2025, and December 31, 2024, related to deferred compensation, payments to third-party service providers, and normal business items.
• Omni Healthcare, Inc., whose principal is an investor in FCHS, was involved in the settlement of lease obligations for First Choice Medical Group of Brevard in Melbourne, Florida, with a verbal agreement for Series C conversion terms.

Stakeholder Impact

• Shareholders face significant dilution from the IPO and potential further dilution from the anti-dilution provisions of the Series D Convertible Preferred Stock, which could depress common stock price.
• Existing common shareholders will experience a 1-for-2,000 reverse stock split, significantly reducing their share count.
• The cancellation of the CEO's Series A Super Voting Preferred Stock will reduce concentrated voting power, potentially benefiting common shareholders by increasing their relative influence.
• New investors in the IPO will acquire Series D Convertible Preferred Stock and Warrants, which are highly speculative and have no established trading market.
• Employees, particularly Nurse Practitioners, are central to the new business model, with plans for hiring and training to support clinic expansion.
• Patients are expected to benefit from expanded access to personalized primary care, wellness, and compounding pharmacy services, with a focus on improved quality of life and customer experience.
• Creditors involved in the bankruptcy proceedings have had their claims settled or converted, with some liabilities being exchanged for Series C Preferred Stock.
• Suppliers to the compounding pharmacy face risks related to consistent demand and regulatory compliance, as the company's growth strategy relies on a single pharmacy initially.

Next Steps

• Complete the public offering of Series D Convertible Preferred Stock and Warrants.
• Obtain NYSE listing approval for common stock.
• Complete the 1-for-2,000 reverse stock split for existing common shares (excluding IPO, resale, and acquisition shares).
• Complete the 100% stock purchase acquisition of Pointe Medical Services, Inc., Pointe Med Pharmacy, Inc., Livewell MD, LLC, and Livewell Drugstore, LLC.
• Complete the asset purchase agreement for The Good Clinic, Inc.
• Appoint new board members (Joseph Clemente, Gary E. Stein, James Hennig, Mara Jacobs) and re-establish Audit, Nominating and Governance, and Compensation Committees.
• Cancel all 4 outstanding shares of Series A Super Voting Preferred Stock held by the CEO.
• Commence operations for the new primary care and wellness clinics strategy by October 1, 2025.
• Expand compounding pharmacy services to include non-patient specific medications (503B status) and increase state licensures.
• Open five clinics by December 2025 and a total of thirty new clinics in the next four years.
• Evaluate Denver and Phoenix markets for potential future expansion opportunities.
• Continue efforts to repair relationships with employees and referral sources.
• Address outstanding legal settlements and liabilities, including those with GMR Melbourne, LLC, CBL & Associates Properties, Inc., MBABJB Holdings Family Limited Partnership, and Ackerman, LLP.

Key Dates

Keywords

Primary Care, Wellness Clinics, Healthcare Solutions, Compounding Pharmacy, IPO, Convertible Preferred Stock, Warrants, SEC Filing, Strategic Pivot, Nurse Practitioners, Anti-aging, Weight Management, Hormone Replacement Therapy, Medical Acquisitions, NYSE Listing, Dilution, Going Concern, Healthcare Regulation, Risk Factors